Christine Bellon - Oct 1, 2025 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
Chief Legal Officer
Signature
By: /s/ Christine Bellon
Stock symbol
BEAM
Transactions as of
Oct 1, 2025
Transactions value $
-$9,150
Form type
4
Date filed
10/3/2025, 04:10 PM
Previous filing
Apr 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bellon Christine Chief Legal Officer C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE By: /s/ Christine Bellon 2025-10-03 0001963878

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Sale -$9.15K -373 -0.32% $24.53 117K Oct 1, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.